Skip to main content

Market Overview

BGI-Shenzhen Receives Approval from Ministry of Commerce of PRC for Proposed Acquisition Of Complete Genomics

Share:

BGI-Shenzhen ("BGI") and Complete Genomics (NASDAQ: GNOM) ("Complete") announced today that they have obtained approval from the Ministry of Commerce of the People's Republic of China regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.

BGI and Complete are awaiting approval of the State Administration of Foreign Exchange of the People's Republic of China regarding the proposed acquisition.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers LLP. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins LLP.

Stockholders with questions about the Offer or who need assistance with tendering their shares of common stock of Complete, may call the Information Agent, Innisfree M&A Incorporated, toll-free, at (888) 750-5834.

FORWARD-LOOKING STATEMENTS

Certain statements either contained in or incorporated by reference into this document are forward-looking statements that involve risks and uncertainty. Future events regarding the proposed transactions and both BGI's and Complete's actual results could differ materially from the forward-looking statements. Factors that might cause such a difference include, but are not limited

See full press release

 

Related Articles (GNOM)

View Comments and Join the Discussion!

Posted-In: M&A News Guidance Asset Sales Management Global

Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com